Trial Profile
Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 May 2017
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Dec 2015 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 23 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to to ClinicalTrials.gov record.
- 27 Aug 2014 Planned End Date changed from 1 Jul 2015 to 1 Sep 2015, according to the ClinicalTrials.gov record.